Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of ...

Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication. "We at Zealand Pharma are acutely aware of the significant unmet medical need for newborns and children with ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

Afrin and Flonase are over-the-counter nasal sprays. Learn how they compare in effectiveness, side effects, and safety to ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...

In the midst of an overdose crisis, organizations are calling for the Saskatchewan government to fund naloxone nasal spray, ...